Physician profile

Thomas D Kaelin

Pulmonary Disease · N Charleston, SC

NPI 1740280841

$34,698.72

in general payments reported to CMS, 2019-2025

58 companies · $1,640 in 2025

The $1,640 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,029.12
Education$189.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $24,078.61 2019-2025 Ofev
Jazz Pharmaceuticals INC. $1,569.90 2019-2025 Xywav
Astrazeneca Uk Limited $1,245.97 2020
Astrazeneca Pharmaceuticals LP $1,088.21 2019-2025 Fasenra, Airsupra, Breztri
Glaxosmithkline, LLC. $769.94 2019-2025 Trelegy Ellipta, Nucala
Harmony Biosciences LLC $708.20 2020-2025 Wakix
Axsome Therapeutics, INC. $587.83 2022-2025 Sunosi
Avadel Cns Pharmaceuticals, LLC $488.71 2023-2025 Lumryz
Mallinckrodt Hospital Products INC. $433.21 2020-2025 Acthar
Regeneron Healthcare Solutions, INC. $402.96 2019-2025 Dupixent
Takeda Pharmaceuticals U.S.A., INC. $341.86 2020-2025 Glassia, Hyqvia
Mylan Specialty L.P. $278.91 2019-2024 Yupelri
Genzyme Corporation $245.32 2019-2024
United Therapeutics Corporation $198.61 2021-2023 Tyvaso
Grifols USA, LLC $185.30 2020-2025 Prolastin-C Liquid, Xembify
Show all 50 companies
CompanyGeneral paymentsYearsTop products
Inari Medical, INC. $175.49 2022
Insmed, INC. $175.19 2021-2025 Arikayce, Brinsupri
Genentech USA, INC. $174.28 2019-2023 Xolair
Vanda Pharmaceuticals INC. $151.95 2021-2022
Csl Behring $142.08 2019-2023 Hizentra
Sunovion Pharmaceuticals INC. $120.53 2019-2020
Actelion Pharmaceuticals US, INC. $114.46 2020-2024 Opsumit, Uptravi
Inspire Medical Systems, INC. $108.65 2023 Inspire
Gilead Sciences, INC. $78.44 2021-2022
Amgen INC. $76.65 2022-2025 Tezspire
Pharming Healthcare, INC. $65.82 2022
Idorsia Pharmaceuticals US INC $63.14 2023-2024 Quviviq
Ani Pharmaceuticals, INC. $56.52 2024-2025 Purified Cortrophin Gel
Resmed Corp $52.12 2019-2022
Shire North American Group INC $48.20 2019
Astellas Pharma US INC $39.48 2020-2021
Inogen, INC. $35.05 2022
Pfizer INC. $34.78 2024-2025
Optinose US, INC. $31.25 2020
Philips North America LLC $30.94 2020
Electromed, INC. $30.43 2019-2025 Smartvest
Vapotherm INC $24.13 2021
Itamar Medical INC $22.57 2025 Watchpatone
Lilly USA, LLC $21.90 2025 Zepbound
Verona Pharma, INC. $21.80 2025 Ohtuvayre
Novartis Pharmaceuticals Corporation $21.74 2023
Apria Healthcare LLC $21.56 2021
Ethicon INC. $20.05 2020
Advanced Respiratory, INC $19.07 2021
Nabriva Therapeutics, Plc $18.64 2021
Paratek Pharmaceuticals, INC. $17.58 2023 Nuzyra
Teva Pharmaceuticals USA, INC. $16.98 2023 Airduo Digihaler
Circassia INC. $16.50 2019
Allergan, INC. $13.90 2019
Almatica Pharma LLC $13.31 2023 Gralise

8 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$1,813.74 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas D Kaelin

$34,698.72

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $1,640 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/123877/thomas-d-kaelin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.